×
NexImmune Pre-Tax Profit Margin 2020-2024 | NEXI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
NexImmune pre-tax profit margin from 2020 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
View More
NexImmune Pre-Tax Profit Margin 2020-2024 | NEXI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
NexImmune pre-tax profit margin from 2020 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$140.4B
Bristol Myers Squibb (BMY)
$114.2B
Gilead Sciences (GILD)
$113.5B
Vertex Pharmaceuticals (VRTX)
$102.1B
CSL (CSLLY)
$83.7B
Regeneron Pharmaceuticals (REGN)
$77.8B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$37.8B
Alnylam Pharmaceuticals (ALNY)
$30.8B
BioNTech SE (BNTX)
$26.5B
Biogen (BIIB)
$21.5B
Illumina (ILMN)
$21.3B
BeiGene (BGNE)
$17B
Moderna (MRNA)
$15.2B
Genmab (GMAB)
$13.3B
Incyte (INCY)
$12.9B
Insmed (INSM)
$12.4B
BioMarin Pharmaceutical (BMRN)
$12.4B
Sarepta Therapeutics (SRPT)
$11.4B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$10.7B
Exact Sciences (EXAS)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.2B
QIAGEN (QGEN)
$10.1B
Exelixis (EXEL)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.9B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8.2B